Table 1.
NP-Based Therapeutics which Follow Passive Targeting
| Trade name | NP Type | Company | Disease | Payload | Current Status / Clinical Trial No. |
|---|---|---|---|---|---|
| CRLX101 | Cyclodextrin-based polymer | Cerulean Pharma Inc. | Solid tumor of various types including pancreatic cancer, ovarian cancer, and non small cell lung cancer | Camptothecin | Phase II/NCT01380769 |
| Doxil® | PEGylated liposome | Janssen Pharmaceuticals | AIDS-related Kaposi’s sarcoma, metastatic ovarian cancer, and multiple myeloma | Doxorubicin | Approved |
| Genexol-PM | Polymer | Samyang Corporation | Breast cancer | Paclitaxel | Phase III/NCT00876486 |
| CPX-1 | Liposome | Celator Pharmaceuticals | Advanced solid tumors in colorectal cancer | Irinotecan- Floxuridine | Phase II/NCT00361842 |
| DaunoXome | Liposome | Galen | AIDS-related Kaposi’s sarcoma | Daunorubicin | Approved |
| Myocet | Non-PEGylated liposome | Enzon Pharmaceuticals | Advanced metastatic breast cancer, ovarian cancer | Doxorubicin | Approved in Europe and Canada |
| LE-SN38 | Liposome | NeoPharm | Metastatic colorectal cancer | SN-38 | Phase III in USA/NCT00294996 |
| Onco TCS | Liposome | INEX and ENZON | Non-Hodgkin’s lymphoma | Vincristine | Approved |
| SPI-77 | Liposome | SEQUUS Pharmaceuticals | Ovarian cancer | Cisplatin | Phase II/NCT00004083 |
| Abraxane | Albumin | Celgene | Metastatic breast cancer | Paclitaxel | Approved |
| NC6004 | Micelle | NanoCarrier | Pancreatic cancer | Cisplatin | Phase I/II /NCT00910741 |
| NK105 | Micelle | Nippon Kayaku Co, Ltd. | Breast cancer | Paclitaxel | Phase III/NCT01644890 |
| NK012 | Polymer Micelle | Nippon Kayaku Co, Ltd. | Solid tumors, Breast cancer | SN-38 | Phase II/NCT00951054 |